Zobrazeno 1 - 10
of 107
pro vyhledávání: '"Sharon, Sams"'
Autor:
Anthony D. Elias, Alyse W. Staley, Monica Fornier, Gregory A. Vidal, Vida Alami, Sharon Sams, Nicole S. Spoelstra, Andrew Goodspeed, Peter Kabos, Jennifer R. Diamond, Elena Shagisultanova, Rosa I. Gallagher, Julia D. Wulfkuhle, Emanuel F. Petricoin, Kathryn L. Zolman, Tessa McSpadden, Kimberly R. Jordan, Jill E. Slansky, Virginia F. Borges, Dexiang Gao, Jennifer K. Richer
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-14 (2024)
Abstract Most ER+ breast cancers (BC) express androgen receptors (AR). This randomized phase II trial of 4 months of neoadjuvant fulvestrant (Fulv) alone or with enzalutamide (Combo) assessed whether adding AR blockade to Fulv would limit residual tu
Externí odkaz:
https://doaj.org/article/564ac0eba47340f495698648097af1b7
Autor:
Ellen E. Bamberg, Mark Maslanka, Kiran Vinod-Paul, Sharon Sams, Erica Pollack, Matthew Conklin, Peter Kabos, Kirk C. Hansen
Publikováno v:
Matrix Biology Plus, Vol 24, Iss , Pp 100162- (2024)
Obesity has reached epidemic proportions in the United States, emerging as a risk factor for the onset of breast cancer and a harbinger of unfavorable outcomes [1–3]. Despite limited understanding of the precise mechanisms, both obesity and breast
Externí odkaz:
https://doaj.org/article/ef60230d21ef4cc4bd37e650ba52dffb
Autor:
Anthony D. Elias, Nicole S. Spoelstra, Alyse W. Staley, Sharon Sams, Lyndsey S. Crump, Gregory A. Vidal, Virginia F. Borges, Peter Kabos, Jennifer R. Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadden, Gloria Crawford, Angelo D’Alessandro, Kathryn L. Zolman, Adrie van Bokhoven, Yonghua Zhuang, Rosa I. Gallagher, Julia D. Wulfkuhle, Emanuel F. Petricoin III, Dexiang Gao, Jennifer K. Richer
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-10 (2023)
Abstract This clinical trial combined fulvestrant with the anti-androgen enzalutamide in women with metastatic ER+/HER2− breast cancer (BC). Eligible patients were women with ECOG 0–2, ER+/HER2− measurable or evaluable metastatic BC. Prior fulv
Externí odkaz:
https://doaj.org/article/ad0c82b5d82a4e81a6170a0a923d1435
Autor:
Jennifer R. Diamond, S. G. Eckhardt, Todd M. Pitts, Adrie van Bokhoven, Dara Aisner, Daniel L. Gustafson, Anna Capasso, Sharon Sams, Peter Kabos, Kathryn Zolman, Tiffany Colvin, Anthony D. Elias, Anna M. Storniolo, Bryan P. Schneider, Dexiang Gao, John J. Tentler, Virginia F. Borges, Kathy D. Miller
Publikováno v:
Breast Cancer Research, Vol 20, Iss 1, Pp 1-10 (2018)
Abstract Background Triple-negative breast cancer (TNBC) remains an aggressive breast cancer subtype with limited treatment options. ENMD-2076 is a small-molecule inhibitor of Aurora and angiogenic kinases with proapoptotic and antiproliferative acti
Externí odkaz:
https://doaj.org/article/b8114fdcf25045a88513879cfaf4520b
Autor:
Jennifer Richer, Nicole Spoelstra, Alyse Winchester, Julia Wulfkuhlue, Rosa Gallagher, Sharon Sams, Gregory Vidal, Peter Kabos, Jennifer Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadded, Gloria Crawford, Virginia Borges, Dexiang Gao, Emanuel Petricoin, Anthony Elias
Publikováno v:
Cancer Research. 82:P1-17
Background: The clinical implications of the androgen receptor (AR), particularly in the context of aromatase inhibitor (AI) refractory metastatic breast cancer (MBC), are unclear. While AR is associated with more indolent primary tumors, in the abse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abe63f468ac7349b194565e8752303fd
https://doi.org/10.1158/1538-7445.sabcs21-p1-17-01
https://doi.org/10.1158/1538-7445.sabcs21-p1-17-01
Autor:
Laura D. Leonard, Ben Himelhoch, Victoria Huynh, Dulcy Wolverton, Kshama Jaiswal, Gretchen Ahrendt, Sharon Sams, Ethan Cumbler, Richard Schulick, Sarah E. Tevis
Publikováno v:
The American Journal of Surgery. 224:27-34
The 21st Century Cures Act requires that institutions release all electronic health information (EHI) to patients immediately. We aimed to understand patient and clinician attitudes toward the immediate release of EHI to patients.Patients and clinici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::403f566d5ea5f1a0598f1b79b4b3cee9
https://doi.org/10.1016/j.amjsurg.2021.12.002
https://doi.org/10.1016/j.amjsurg.2021.12.002
Autor:
Sudheer Vemuru, Jin Huang, Kathryn Colborn, YooJin Yoon, Victoria Huynh, Laura Leonard, Gretchen Ahrendt, Nicole Christian, Anosheh Afghahi, Lauren McLemore, Sharon Sams, Sarah Tevis
Publikováno v:
Breast Cancer Research and Treatment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6051881b762fb3e5c2d69c45e7b0fca5
https://doi.org/10.1007/s10549-023-06978-0
https://doi.org/10.1007/s10549-023-06978-0
Autor:
Alanna Mayberry, Eduardo Antônio Donadi, Melissa L Ledezma, David J. Orlicky, Jacob Calhoun, Bruna Cristina Bertol, Elise S. Bales, Sharon Sams, Jena D. French, Bryan R. Haugen
Publikováno v:
Thyroid
Background: Combination therapy with lenvatinib plus programmed death-1 (PD-1) immune checkpoint blockades (ICBs) is under investigation in many solid tumors, including thyroid cancer. Lenvatinib is known to reduce angiogenesis and may overturn the i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6443dd7627a13a715922386ab66330bc
https://doi.org/10.1089/thy.2021.0371
https://doi.org/10.1089/thy.2021.0371
Autor:
Elizabeth O'Brien, Sudheer Vemuru, Laura Leonard, Ben Himelhoch, Nancy Taft, Kshama Jaiswal, Ethan Cumbler, Sharon Sams, Dulcy Wolverton, Gretchen Ahrendt, Jeniann Yi, Chen-Tan Lin, Randy Miles, Karen Hampanda, Sarah Tevis
Introduction: As part of the 21st Century Cures Act, beginning April 2021, electronic health information (EHI) must be immediately released to patients. This change poses challenges for both oncology clinicians and patients whose priorities and exper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::146095101e967a9befd50f5c2e1c8f13
https://doi.org/10.21203/rs.3.rs-2406931/v1
https://doi.org/10.21203/rs.3.rs-2406931/v1
Autor:
Anthony D. Elias, Alyse Staley, Monica Fornier, Gregory A. Vidal, Sharon Sams, Nicole Spoelstra, Peter Kabos, Jennifer R. Diamond, Elena Shagisultanova, Rosa I. Gallagher, Julia Wulfkuhle, Emanuel Petricoin, Kathryn Zolman, Stephanie Biller, Vida Alami, Tessa McSpadden, Virginia Borges, Lyndsey S. Crump, Dexiang Gao, Jennifer K. Richer
Publikováno v:
Cancer Research. 83:CT144-CT144
Background: Most estrogen receptor alpha positive (ER+) breast cancers (BCs) express androgen receptor (AR) protein, but its function is unclear. High AR relative to ER is associated with endocrine resistance. This randomized phase II trial of neoadj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85340548b90a85832ba4e5ded420688f
https://doi.org/10.1158/1538-7445.am2023-ct144
https://doi.org/10.1158/1538-7445.am2023-ct144